Wednesday, April 30, 2014 8:50:54 AM
Many Shareholders have asked that I post a simple easy to read non-technical clarification of $ELTP 1st generation 3 Patents.
8,182,836 Patent….Patent Application 12/478,952
This is the 1st of the Triple Patents and has been awarded to $ELTP based on its ADT Pharmacological approach of neutralizing opioid agonist abuse with an opioid antagonist that have been administered together.
8,425,933 Patent….Patent Application 12/640,344
This is the 2nd of the Triple Patents and has been awarded to $ELTP based on its 2-bead modular approach of identical physical attributes for separate agonist bead and an antagonist bead. This 2-bead tech is $ELTP Preferred Embodiment and is graphically illustrated on $ELTP website.
http://www.elitepharma.com/How_AR_Tech_Works.pdf
8,703,186 Patent….Patent Application 13/863,764
This is the 3rd of the Triple Patents and has been awarded to $ELTP based specifically on the manufacturer details for the 50 mg Naltrexone bead and its sequestering polymer to absolutely minimize Naltrexone leakage. The 50 mg Naltrexone bead is premade and can be used with any agonist opioid both type and expected dosage ranging up to 24 HR ER. The Preferred Embodiment supports the 2-bead modular technology outlined in $ELTP’s 8,425,933 Patent where unidentifiable agonist and antagonist beads are mixed together in one capsule.
In addition general broad-brush reference is made to a non-modular single bead technology manufactured with layering the agonist on to the antagonist but no specific manufacturing illustrations are given that can actually be patented. So it remains as a trade-secret or basis for a possible future single bead patent or simply $ELTP keeping its R&D “possibilities” open.
I hope this helps explains the reasons for the 3 patents. I will over time update this explanation as needed. Any questions please ask.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM